Michael Attubato, MD

Benefits & Controversies: The REPLACE-2 Trial

06/19/2008

The primary endpoint was the 30-day incidence of death, MI, urgent revascularization and major hemorrhage, which occurred in 9.2% of patients in the bivalirudin arm and 10.0% of patients in the heparin-IIb/IIIa arm. The trial had a...

The primary endpoint was the...

06/19/2008

Cath Lab Digest

Feature

Benefits & Controversies: The REPLACE-2 Trial

06/19/2008

Michael Attubato , MD;

The primary endpoint was the...

06/19/2008

Cath Lab Digest

Original Contribution

Invasive Management of Acute Myocardial Infarctions During the Initial Wave of the COVID-19 Pandemic

01/03/2022

Sripal Bangalore , MD, MHA;

Michael Attubato , MD;

Nina Talmor , MD;

Abhinay Ramachandran , MD, MS;

Shari B. Brosnahan , MD;

Louai Razzouk , MD, MPH;

Nathaniel R. Smilowitz , MD, MS;

Craig A. Thompson , MD, MMSc;

Frederick Feit , MD;

Binita Shah , MD, MS;

The initial wave of the coronavirus disease 2019 (COVID-19) pandemic resulted in an influx of patients with acute viral illness and profound changes in healthcare delivery in New York City. The impact of this pandemic on the presentation and...

The initial wave of the...

01/03/2022

Journal of Invasive Cardiology